Decernotinib clinical trials
Also written VX-509.
How each study uses decernotinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- VX-509
- 6
Studies by the year they started
6 studies that test it; most in 2013 (3)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2010 | 1 |
| 2012 | 1 |
| 2013 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses decernotinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- 24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking MethotrexateCompletedPhase 2Vertex Pharmaceuticals IncorporatedNCT01590459Written as VX-509
- A Phase 2/3 Open-label Extension Study to Evaluate Long-Term Safety and Efficacy With VX-509 in Subjects With Rheumatoid ArthritisCompletedPhase 2/3Vertex Pharmaceuticals IncorporatedNCT01830985Written as VX-509
- A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 InhibitorCompletedPhase 2Vertex Pharmaceuticals IncorporatedNCT01754935Written as VX-509
- Phase 1 PK Interaction Study Between VX-509 and Prednisone or Methylprednisolone in Healthy Male SubjectsCompletedPhase 1Vertex Pharmaceuticals IncorporatedNCT01886209Written as VX-509
- A 12-week Study of 4 Doses of VX-509 in Subjects With Active Rheumatoid ArthritisCompletedPhase 2Vertex Pharmaceuticals IncorporatedNCT01052194Written as VX-509
- Single and Multiple Dose Escalation Study of VX-509 in Healthy SubjectsCompletedPhase 1Vertex Pharmaceuticals IncorporatedNCT00789126Written as VX-509
Codes
What other systems call decernotinib · ClinicalTrials.gg INT000205
- UNII (FDA) MZK2GP0RHKDECERNOTINIBConfirmed FDA, Wikidata
- Wikidata Q27077006decernotinibConfirmed FDA, Wikidata
- NCI Thesaurus C132740DecernotinibOne source FDA
- DrugBank DB12566One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | MZK2GP0RHK | DECERNOTINIB | Confirmed FDA, Wikidata |
| Wikidata | Q27077006 | decernotinib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C132740 | Decernotinib | One source FDA |
| DrugBank | DB12566 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.